+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07148791

Phase 2 Study of Anti-BCMA-CD19 CAR-T Cell Therapy for Adults With Relapsed or Refractory IgG4-Related Disease

Led by Chinese PLA General Hospital · Updated on 2025-09-03

9

Participants Needed

1

Research Sites

121 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a new immune cell therapy called anti-BCMA-CD19 CAR-T cells in adults aged 18 to 75 years with IgG4-related disease IgG4-RD that has returned or not improved after standard treatments like glucocorticoids or rituximab. This Phase 2, open-label, single-arm study aims to assess the safety and preliminary effectiveness of this therapy by monitoring side effects and changes in disease activity scores at 12 and 26 weeks. IgG4-RD is a chronic disorder affecting multiple organs and sometimes resists conventional treatments, creating a need for new options. Participants will have their blood immune cells collected through leukapheresis, which are then modified outside the body to target disease-causing cells. Before receiving the therapy, they will get chemotherapy with cyclophosphamide and fludarabine for three days to prepare their immune system. On Day 0, participants will receive a single intravenous infusion of the anti-BCMA-CD19 CAR-T cells at one of three dose levels. After infusion, they will have safety and efficacy monitoring visits up to 52 weeks. Throughout the study, participants will attend regular clinic visits for safety evaluations, blood tests, and imaging to monitor treatment effects and side effects, including specific immune responses and cell counts. Researchers will assess dose-limiting toxicities within 28 days and changes in disease activity scores at 12 and 26 weeks. Secondary measures include monitoring the presence and activity of CAR-T cells, lesion size, and blood markers. Some participants may be followed for up to one year to better understand long-term effects.

CONDITIONS

Brief Title

Exploratory Study of Anti-BCMA-CD19 CAR-T Cell Therapy in Relapsed or Refractory IgG4-Related Disease

Research Team

Y

YIWEN WANG, M.D.

Y

YUFEI GUO, M.M.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here